Decoy Therapeutics announces that Massachusetts Institute of Technology, MIT, Professor and Moderna co-founder Robert Langer, ScD will join the company’s Scientific Advisory Board, SAB, upon the successful completion of Decoy’s merger with Salarius Pharmaceuticals (SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with the newly formed company to be named Decoy Therapeutics.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue